Free Trial
NASDAQ:ALRN

Aileron Therapeutics (ALRN) Stock Price, News & Analysis

Aileron Therapeutics logo
$1.75 -0.01 (-0.57%)
(As of 12/20/2024 05:15 PM ET)

About Aileron Therapeutics Stock (NASDAQ:ALRN)

Key Stats

Today's Range
$1.70
$1.88
50-Day Range
$1.75
$4.12
52-Week Range
$1.61
$7.42
Volume
71,500 shs
Average Volume
75,366 shs
Market Capitalization
$37.92 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.00
Consensus Rating
Strong Buy

Company Overview

Aileron Therapeutics, Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate is LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Austin, Texas.

Aileron Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
61st Percentile Overall Score

ALRN MarketRank™: 

Aileron Therapeutics scored higher than 61% of companies evaluated by MarketBeat, and ranked 405th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Aileron Therapeutics has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Aileron Therapeutics has received no research coverage in the past 90 days.

  • Read more about Aileron Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Aileron Therapeutics are expected to grow in the coming year, from ($1.56) to ($1.41) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Aileron Therapeutics is -0.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Aileron Therapeutics is -0.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Aileron Therapeutics has a P/B Ratio of 1.24. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.92% of the float of Aileron Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Aileron Therapeutics has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Aileron Therapeutics has recently decreased by 1.05%, indicating that investor sentiment is improving.
  • Dividend Yield

    Aileron Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Aileron Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.92% of the float of Aileron Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Aileron Therapeutics has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Aileron Therapeutics has recently decreased by 1.05%, indicating that investor sentiment is improving.
  • Search Interest

    Only 1 people have searched for ALRN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Aileron Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Aileron Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $896.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    Only 5.10% of the stock of Aileron Therapeutics is held by insiders.

  • Percentage Held by Institutions

    90.89% of the stock of Aileron Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Aileron Therapeutics' insider trading history.
Receive ALRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aileron Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ALRN Stock News Headlines

Did You See Trump’s Bombshell Exec. Order 001?
Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."
See More Headlines

ALRN Stock Analysis - Frequently Asked Questions

Aileron Therapeutics' stock was trading at $3.05 on January 1st, 2024. Since then, ALRN stock has decreased by 42.6% and is now trading at $1.75.
View the best growth stocks for 2024 here
.

Aileron Therapeutics, Inc. (NASDAQ:ALRN) issued its quarterly earnings data on Wednesday, August, 14th. The company reported ($0.45) earnings per share for the quarter, missing analysts' consensus estimates of ($0.25) by $0.20.

Aileron Therapeutics shares reverse split on Thursday, November 10th 2022. The 1-20 reverse split was announced on Thursday, November 10th 2022. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 10th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Aileron Therapeutics (ALRN) raised $61 million in an initial public offering on Thursday, June 29th 2017. The company issued 3,800,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch and Jefferies acted as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.

Top institutional shareholders of Aileron Therapeutics include Geode Capital Management LLC (1.06%), Sigma Planning Corp (0.98%) and KG&L Capital Management LLC (0.06%). Insiders that own company stock include Of Texas/Texas Am I University and James Brian Windsor.
View institutional ownership trends
.

Shares of ALRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Aileron Therapeutics investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), NIO (NIO), AST SpaceMobile (ASTS), Virgin Galactic (SPCE) and Phunware (PHUN).

Company Calendar

Last Earnings
8/14/2024
Today
12/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ALRN
Fax
N/A
Employees
9
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$19.00
High Stock Price Target
$19.00
Low Stock Price Target
$19.00
Potential Upside/Downside
+985.7%
Consensus Rating
Strong Buy
Rating Score (0-4)
3.50
Research Coverage
2 Analysts

Profitability

Net Income
$-15,730,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.41 per share

Miscellaneous

Free Float
20,561,000
Market Cap
$37.92 million
Optionable
Not Optionable
Beta
2.22
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

This page (NASDAQ:ALRN) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners